drug discovery

A unique collection of 2975 approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 2850 GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research;

A unique collection of 1796 annotated bioactive compounds with clear targets, suitable for phenotypic screening;

A unique collection of 280 bioactive compounds specifically targeting adrenergic receptors, effective tool for screening new drugs or new target identification;

Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species (ROS) and a biological system's ability to readily detoxify the reactive intermediates or repair the resulting damage. Disturbances in the normal redox state of cells can cause toxic effects through the production of peroxides and free radicals that damage all components of the cell, including proteins, lipids, and DNA. In humans, oxidative stress is thought to be involved in the development of atherosclerosis, heart failure, myocardial infarction, cancer, infection etc. Antioxidants are a class of compounds that counteract oxidative stress and reduce oxidative damage. The TargetMol Antioxidant Compound Library is a unique collection of 2010 small molecules with inhibitory effects on oxidative stress and is a useful tool for high-throughput screening and high-content screening in the study of oxidative stress.

A unique collection of 101 compounds with defined hematopoietic toxicity for high throughput and high content drug screening;

A unique collection of 701 preclinical compounds for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 569 histone modification related compounds for high throughput screening (HTS) and high content screening (HCS);

A collection of 27752 bioactive compounds for high-throughput screening, high-content screening, cell induction and target identification.

TargetMol created the L4020 NO-PAINS Compound Library that applied the PAINS filter, remaining 9384 small molecules that are suitable for new drug development, signaling pathway research, drug repurposing and other research.

A unique collection of 485 PPI-related compounds for drug screening;

A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.

A unique collection of 1490 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening;

A unique collection of 3660 drugs with anti-cancer activity or potential anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1960 FDA approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 535 antifungal compounds effective for drug repurposing screening, combination screening and biological investigation.

A unique collection of 861 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;

A unique collection of 631 nuclear receptor signaling targeted compounds for high throughput and high content screening;

A unique collection of 1920 approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 1268 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS);

A unique collection of 573 cancer cell differentiation inducing compounds for high throughput and high content screening;

A unique collection of 2440 compounds with anti-breast cancer therapeutic activity or targeting breast cancer's major signaling pathways, can be used for anti-breast cancer drug discovery and mechanism study;

A unique collection of 2508 pancreatic cancer related compounds can be used in HTS and HCS;

1880 compounds associated with colorectal cancer that can be used for high-throughput and high-content screening.